OSR Holdings agrees to buy VXM01 intellectual property assets from Vaximm for $30 million

• OSR Holdings signed an asset purchase deal on May 27, 2026 to buy Vaximm’s VXM01 intellectual property portfolio for USD 30 million.
• Assets include patents, know-how, regulatory filings, clinical data, and certain related contracts tied to the VXM01 cancer immunotherapy program.
• Payment is due when the first milestone under the April 29, 2026 global license is triggered, tied to completing a Phase 2 study in GBM or PDAC.
• Closing is set to occur upon that first milestone payment, positioning OSR as the direct recipient of future milestones and royalties.
• Either party can terminate if closing has not occurred by Dec. 31, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-064037), on June 02, 2026, and is solely responsible for the information contained therein.